Atea Pharmaceuticals (AVIR) EBITDA (2019 - 2026)

Atea Pharmaceuticals' EBITDA history runs 8 years deep, the most recent figure standing at -$48.0 million for Q1 2026.

• On a quarterly basis, EBITDA fell 22.97% year-over-year to -$48.0 million in Q1 2026; TTM through Mar 2026 was -$189.9 million, a 17.06% decrease from a year earlier, with the FY2025 full-year figure at -$180.9 million, up 6.25% from the prior year.
• EBITDA advanced to -$48.0 million in Q1 2026 per AVIR's latest filing, from -$54.9 million in the prior quarter.
• Across five years, EBITDA topped out at -$16.3 million in Q3 2022 and bottomed at -$69.8 million in Q1 2024.
• The 5-year median for EBITDA is -$41.3 million (2025), against an average of -$42.2 million.
• Across the five-year window, EBITDA sank 471.76% in 2022 and jumped 44.07% in 2025, its largest moves.
• Year by year, EBITDA stood at -$39.9 million in 2022, then declined by 16.73% to -$46.6 million in 2023, then increased by 16.2% to -$39.0 million in 2024, then plunged by 40.76% to -$54.9 million in 2025, then gained by 12.61% to -$48.0 million in 2026.
• Per Business Quant, the three latest AVIR EBITDA figures stand at -$48.0 million (Q1 2026), -$54.9 million (Q4 2025), and -$45.6 million (Q3 2025).